Sanofi - American Depositary Shares (SNY)

Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This notable drop came on the heels of the company's announcement and pricing of a substantial public stock offering, a move that

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation.

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025.

Sanofi reports show significant improvements in hidradenitis suppurativa symptoms, with higher response rates and reduced lesions.

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.

The company is working on a treatment for an autoimmune disease that affects the muscles.

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential.

Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.

Can anything beat out Dupixent's "compelling bar" for effectiveness?

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to district court for further proceedings.

Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.